Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Suzette Delgado

Obstetrics & Gynecology Miami, FL Medical Doctor

NPI 1326304510 CMS profile 1382802

10700 N Kendall Dr, Ste 200, Miami, FL 33176

Open in the dashboard

General payments

$7,414

155 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Suzette Delgado of Miami, FL is reported in the CMS Open Payments database as having received $7,414 across 155 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $596 26
2024 General $4,510 26
2023 General $479 22
2022 General $486 23
2021 General $556 28
2020 General $137 8
2019 General $648 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suzette Delgado
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Suzette Delgado were reported at $596. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Suzette Delgado Obstetrics & Gynecology median Middle half National median
2019 $648 $172 $62–$391 $163
2020 $137 $94 $36–$222 $114
2021 $556 $136 $42–$369 $132
2022 $486 $160 $50–$433 $149
2023 $479 $169 $56–$423 $160
2024 $4,510 $152 $50–$371 $164
2025 $596 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Olympus America Inc. $3,979 1 payment
  2. AbbVie, Inc. $966 40 payments
  3. Astellas Pharma US Inc $361 14 payments
  4. Biogen, Inc. $344 15 payments
  5. Hologic, LLC $178 8 payments
  6. Pfizer Inc. $177 8 payments
  7. Ethicon US, LLC $160 3 payments
  8. CooperSurgical, Inc. $137 8 payments
  9. Smith+Nephew, Inc. $136 6 payments
  10. Sumitomo Pharma America, Inc. $132 7 payments
  11. Other $843 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Debt forgiveness $3,979 1 payment
  2. Food and Beverage $3,342 152 payments
  3. Education $92 2 payments
Products named General payments · program years 2019–2025
  1. Olympus $3,979 1 payment
  2. LO LOESTRIN FE $397 24 payments
  3. Orilissa $295 6 payments
  4. Zurzuvae $294 13 payments
  5. Veozah $255 11 payments
  6. ORIAHNN $213 8 payments
  7. MYFEMBREE $132 7 payments
  8. PREMARIN $128 6 payments
  9. Aptima $120 5 payments
  10. STRAVIX $110 5 payments
  11. Other $1,785 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record